Centers | ||
Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Centre for Collaborative Drug Research |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
The Centre for Collaborative Drug Research is a multidisciplinary initiative bringing together the Faculties of Medicine and Pharmacy at the University of Toronto, Canadas leading academic institution and largest research entity, and the Centre... |
Partnerships |
Events |
Jobs |
Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Astra Zeneca and University of Pennsylvania Partner to Develop Treatments to Manage ObesityAstra Zeneca has entered into a research collaboration agreement with University of Pennsylvania's Institute for Diabetes, Obesity and Metabolism to develop small and or large molecules to manage obesity, control glucose and lipid metabolism in... View all |
No EVENTS for listing |
No Job Posts |


